Real‑world analysis of Macular Oedema associated with Paclitaxel Formulations using the Japanese Adverse Drug Event Report database Authors: Koki Takeda, Toshinori Hirai, Ayu Sugioka, Rinka Okamura, Asako Nishimura, Nobuhito Shibata, Junzheng Yang, Junzheng Yang, Junzheng Yang Published: 2026 ABSTRACT AimThis study explored the potential association between paclitaxel (PTX) and macular oedema (ME), a rare adverse event, through pharmacovigilance analysis using a large-scale spontaneous reporting database.MethodsDisproportionality analysis of ME associated with PTX formulations, including nanoparticle albumin-bound PTX (nab‑PTX) was conducted using the Japanese Adverse Drug Event Report database on data collected during April 2004–June 2025. Multivariable logistic regression analysis was used to estimate adjusted reporting odds ratios (RORs) for ME. A positive signal was defined as a lower 95% confidence interval (CI) for the ROR exceeding 1.0 with at least three ME cases.ResultsAmong 585,738 reports, 123 involved ME. A significant signal was observed for overall PTX (adjusted ROR: 19.5; 95% CI: 13.5–28.3). By formulation, significant signals were identified for conventional PTX (adjusted ROR: 9.4; 95% CI: 5.5–16.1) and nab‑PTX (adjusted ROR: 47.0; 95% CI: 30.4–72.8). Multivariable logistic regression indicated significant signals for diabetes mellitus (adjusted ROR: 1.8; 95% CI: 1.2–2.9) and co-administration of prostaglandin analogue eye drops (adjusted ROR: 19.9; 95% CI: 8.6–45.7).ConclusionPTX formulations were associated with an increased reporting signal of ME. Notably, patients with diabetes mellitus and those using prostaglandin analogue eye drops may require closer ophthalmologic monitoring during PTX therapy. Introduction Macular oedema (ME) involves swelling of part of the retina, the light‑sensitive tissue at the back of the eye [1], which can cause visual impairment and markedly reduce quality of life, potentially leading to irreversible blindness in critical cases [2]. The pathophysiology of ME is multi-factorial, involving diabetes mellitus, age‑related macular degeneration, retinitis pigmentosa, uveitis, retinal vein occlusion, ocular surgery and certain medications, including paclitaxel (PTX) [3–9]. Reports of drug‑induced ME are increasing; it can occur unpredictably and is often overlooked in clinical practice [10]. PTX has been reported to induce ME; it binds to tubulin, promoting microtubule polymerisation, which can disrupt retinal pigment epithelial function and cause severe ocular damage [11]. PTX serves as a primary cytotoxic compound integral to established chemotherapy protocols for non-small cell lung cancer (NSCLS) and ovarian cancer [12,13], whereas nanoparticle albumin-bound paclitaxel (nab‑PTX) is used as a core chemotherapy regimen for NSCLS and pancreatic cancer [12,14]. However, evidence of PTX‑induced ME from large‑scale analyses remains limited, with only small case reports published [15,16]. ME is a rare adverse event, reported in 0.1%–0.4% of cases [17], making evaluation of PTX-associated ME in clinical trials challenging and restricting efforts to prevent ME in clinical practice. The Japanese Adverse Drug Event Report (JADER) database is a spontaneous adverse drug reaction reporting system with extensive and diverse data, allowing hypothesis generation on risk factors for PTX-associated ME. In the present pharmacovigilance study, signal detection analysis of PTX-associated ME was conducted using this database. The analysis aimed to identify potential risk factors and generate hypotheses to guide clinical monitoring and mitigation strategies for ME cases. Materials and methods Study population and data collection Adverse event (AE) data were obtained from the JADER database on the Pharmaceuticals and Medical Devices Agency (PMDA) website (http://www.pmda.go.jp/), which is fully anonymised by the PMDA. Individual informed consent was not required as JADER is a publicly accessible database. The JADER database comprised 1,615,041 spontaneous reports integrating demographic information (DEMO), drug administration information, comorbidity information and AE information collected during April 2004–June 2025 (Fig 1). The analysed dataset was obtained after applying the following exclusion criteria: (1) reports with missing data on sex, age, body weight or reporting year; (2) reports of AEs associated with docetaxel or cabazitaxel; and (3) reports where conventional PTX and nab‑PTX were both registered. Data were pre-screened to remove duplicates and incomplete entries. In the DEMO dataset, age was categorised in 10-year increments, whereas body weight was recorded in 10‑kg intervals. Flowchart of patient selection. Analysed dataset comprised 585,738 reports after excluding (1) records with missing data (n = 1,012,753), (2) reports involving docetaxel or cabazitaxel (n = 16,504) and (3) reports with simultaneous registration of PTX and nab-PTX (n = 46) from the original 1,615,041 reports. In total, 123 cases of ME were identified. AE detection The Japanese version of the Medical Dictionary for Regulatory Activities (MedDRA/J v28.1) was employed as the standardised terminology for coding and analysing AE data. ME events were defined using the preferred term codes for ‘macular oedema’ [10025415] and ‘cystoid macular oedema’ [10058202]. Extracted variables included sex, age, body weight, reporting year, co-existing diabetes mellitus, concomitant prostaglandin analogue eye drop use and ME occurrence. Co-existing diabetes mellitus was specifically defined using preferred terms in the Standardised MedDRA Query for both ‘hyperglycaemia’ and ‘new onset diabetes mellitus’ [20000041]. Statistical analysis The signal for ME occurrence was evaluated using disproportionality analysis with a two-by-two contingency table for PTX formulations (conventional PTX and nab-PTX). Reporting odds ratios (RORs) and corresponding 95% confidence intervals (CIs) were calculated according to equations (1) and (2): where a represents patients receiving the target drug with ME, b represents those not receiving the target drug with ME, c represents those receiving the target drug without ME and d represents those not receiving the target drug without ME. A positive signal was defined as a lower 95% CI for the ROR exceeding 1.0 with a minimum of three ME cases [18]. Multivariable logistic regression analysis was performed to calculate adjusted RORs of ME for PTX formulations, incorporating covariates including sex, age (≥70 years), body weight (<50 kg), co-existing diabetes mellitus and co-administration of prostaglandin analogue eye drops. Covariates were selected based on previous studies [3,19–21]. All statistical analyses were performed using R (v4.5.2), with P < 0.05 considered statistically significant. Results Study population Fig 1 presents a flowchart summarising the selection of the study population. The JADER dataset initially comprised 1,615,041 reports. After applying the following exclusion criteria, 585,738 reports were retained: (1) missing data on sex, age, body weight and reporting year (n = 1,012,753); (2) use of docetaxel or cabazitaxel (n = 16,504); and (3) simultaneous registration of conventional PTX and nab-PTX (n = 46). In the final dataset, 123 reports of ME were identified. Table 1 summarises the clinical characteristics of the study population. Among the reports, 308,573 (52.68%) were for male patients, 246,824 (42.14%) involved patients aged ≥70 years and 203,737 (34.78%) involved patients weighing <50 kg. Reports for patients receiving the study drugs totalled 16,192 (2.76%), including 11,563 (1.97%) with conventional PTX and 4,629 (0.79%) with nab‑PTX. Co-existing diabetes mellitus was reported in 79,493 cases (13.57%) and 1,770 reports (0.30%) involved co-administered prostaglandin analogue eye drops. 10.1371/journal.pone.0354959.t001Table 1Clinical characteristics in the analysis dataset.Variablen = 585,738Sex Male308573 (52.68) Female277165 (47.32)Age, years <1025166 (4.30) 10–1916804 (2.87) 20–2917193 (2.94) 30–3927475 (4.69) 40–4942016 (7.17) 50–5974331 (12.69) 60–69135929 (23.21) 70–79161449 (27.56) 80–8975189 (12.84) 90–9910042 (1.71) >100144 (0.02)Body weight, kg <1012082 (2.06) 10–198616 (1.47) 20–297090 (1.21) 30–3939352 (6.72) 40–49136597 (23.32) 50–59179654 (30.67) 60–69123361 (21.06) 70–7951873 (8.86) 80–8917000 (2.90) 90–995759 (0.98) 100–1092071 (0.35) 110–119849 (0.14) 120–129334 (0.06) 130–139147 (0.03) 140–149187 (0.03) 150–159346 (0.06) 160–169227 (0.04) 170–17998 (0.02) 180–18920 (0.00) 190–1992 (0.00) >20073 (0.00)Diabetes mellitus79493 (13.57)PTX formulations16192 (2.76) PTX11563 (1.97) nab-PTX4629 (0.79)Prostaglandin analogue eye drop1770 (0.30)Abbreviations: PTX, paclitaxel; nab-PTX, nab-paclitaxel.Data are presented as numbers (%). Clinical characteristics in the analysis dataset. Abbreviations: PTX, paclitaxel; nab-PTX, nab-paclitaxel. Data are presented as numbers (%). Disproportionality analysis of PTX formulations for ME Table 2 presents the disproportionality analysis results for PTX-associated ME. Multivariable logistic regression analysis revealed a positive signal for overall PTX formulations (adjusted ROR: 19.5; 95% CI: 13.5–28.3). By formulation, positive signals were observed for conventional PTX (adjusted ROR: 9.4; 95% CI: 5.5–16.1) and nab‑PTX (adjusted ROR: 47.0; 95% CI: 30.4–72.8). 10.1371/journal.pone.0354959.t002Table 2Reporting odds ratios for macular oedema associated with paclitaxel formulations. With MEWithout MEROR95% CIAdjusted ROR95% CIPTX formulations4416,14819.613.6–28.419.513.5–28.3PTX1611,54710.05.8–17.19.45.5–16.1nab-PTX284,60143.928.5–67.647.030.4–72.8Reference79569,4671–1–ME, macular oedema; ROR, reporting odds ratio; 95% CI, 95% confidence interval; PTX, paclitaxel; nab-PTX, nab-paclitaxel.The number of patients with and without macular oedema in each category are presented.A multivariable logistic regression model was used to determine the adjusted ROR by introducing sex, age (>70 years), body weight (<50 kg), diabetes mellitus, and co-administration of medications (paclitaxel/nab-paclitaxel and prostaglandin analogue eye drop). Reporting odds ratios for macular oedema associated with paclitaxel formulations. ME, macular oedema; ROR, reporting odds ratio; 95% CI, 95% confidence interval; PTX, paclitaxel; nab-PTX, nab-paclitaxel. The number of patients with and without macular oedema in each category are presented. A multivariable logistic regression model was used to determine the adjusted ROR by introducing sex, age (>70 years), body weight (<50 kg), diabetes mellitus, and co-administration of medications (paclitaxel/nab-paclitaxel and prostaglandin analogue eye drop). Table 3 shows the multivariable logistic regression analysis results considering clinical characteristics. In addition to PTX use, positive signals were detected for co-existing diabetes mellitus (adjusted ROR: 1.8; 95% CI: 1.2–2.9) and co-administration of prostaglandin analogue eye drops (adjusted ROR: 19.9; 95% CI: 8.6–45.7). 10.1371/journal.pone.0354959.t003Table 3Multivariable logistic regression analysis for signals of macular oedema associated with paclitaxel formulations. With MEWithout MEAdjusted ROR95% CIPTX formulations4416,14819.513.5–28.3Sex, male55308,5180.80.5–1.1Age ≥ 70 years39246,7850.60.4–0.9Body weight <50 kg42203,6951.00.7–1.5Diabetes mellitus2579,4681.81.2–2.9Prostaglandin analogue eye drop61,76419.98.6–45.7Reference79569,4671.0–ME, macular oedema; ROR, reporting odds ratio; 95% CI, 95% confidence interval; PTX, paclitaxel.The number of patients with and without macular oedema in each category are presented.A multivariable logistic regression model was used to determine the adjusted ROR by introducing sex, age (≥70 years), body weight (<50 kg), diabetes mellitus, and co-administration of medications (paclitaxel/nab-paclitaxel and prostaglandin analogue eye drop). Multivariable logistic regression analysis for signals of macular oedema associated with paclitaxel formulations. ME, macular oedema; ROR, reporting odds ratio; 95% CI, 95% confidence interval; PTX, paclitaxel. The number of patients with and without macular oedema in each category are presented. A multivariable logistic regression model was used to determine the adjusted ROR by introducing sex, age (≥70 years), body weight (<50 kg), diabetes mellitus, and co-administration of medications (paclitaxel/nab-paclitaxel and prostaglandin analogue eye drop). Discussion To our knowledge, this is the first study to identify a signal of ME associated with PTX formulations using the JADER database. PTX-associated ME appears more likely to occur in patients with diabetes mellitus and in those using prostaglandin analogue eye drops. The pathogenesis of ME involves fluid accumulation within the outer plexiform and inner nuclear layers [22]. In diabetic ME, vascular endothelial growth factor signalling further compromises the blood–retinal barrier by promoting inflammatory pathways. Accordingly, diabetic ME responds to anti‑vascular endothelial growth factor (VEGF) inhibitors [23]. In contrast, PTX formulations may directly damage the retinal pigment epithelium and Müller cells, both essential for maintaining the blood–retinal barrier [24]. Therefore, early detection of PTX-associated ME is critical, as anti-VEGF inhibitors are ineffective in PTX-induced cases [16]. As shown in S1 Table, overall PTX formulations were the most frequently reported drugs associated with ME in the analysed dataset. Our analysis revealed positive signals for overall PTX as well as for each formulation. Although direct comparisons between PTX formulations are limited in this study, nab‑PTX has been reported to confer a higher risk of peripheral neuropathy compared with conventional PTX [24]. This difference is thought to reflect formulation characteristics, as conventional PTX is dissolved in polyoxyethylated castor oil, whereas nab‑PTX is bound to human serum albumin [17,25]. The increased peripheral neuropathy risk may relate to altered immune responses and tissue distribution. In a large-scale study of 14,260 patients treated with taxanes, ME incidence was significantly higher with nab‑PTX than with PTX (0.4% vs. 0.1%) [17]. Previous studies have also reported a dose-dependent pattern in PTX-associated ME [15]. In breast cancer, the body surface area–adjusted dose of both conventional PTX and nab-PTX is higher than that in other regimens, warranting particular caution [26,27]. Although definitive conclusions regarding comparative ME risk between PTX formulations cannot be drawn, clinicians should remain vigilant irrespective of formulation. In addition, the data on PTX dosage and treatment duration were unavailable in our analysis. Since the cumulative dosage of PTX has been reported to be associated with the development of ME, these variables may be required for further analysis aimed at the early detection of ME [28]. Among reports of PTX-induced ME, breast cancer was the most common malignancy (S2 Table). For cases receiving conventional PTX, carboplatin and bevacizumab were frequently co-administered. However, limited evidence exists regarding ME risk stratified by cancer types or concomitant anti-cancer therapy. Although several case reports have described ME during combination regimens, PTX has consistently been implicated rather than accompanying agents [29,30]. Conversely, pancreatic cancer accounted for the highest number of reports in the nab-PTX subgroup (S3 Table). Gemcitabine plus nab-PTX constitutes a cornerstone chemotherapy regimen for pancreatic cancer [31]. Prior studies have suggested that nab‑PTX possesses intrinsic retinal toxicity [32,33]. In the present dataset, limited case numbers precluded sensitivity analyses by cancer type or co‑administrated anti-cancer agents. Further large-scale analyses are needed to clarify ME risk across subgroups. Multivariable analysis identified diabetes mellitus and prostaglandin analogue eye drops as additional positive signals for ME. Hyperglycaemia has been associated with increased chemotherapy‑related AEs and diabetes mellitus is known to exacerbate PTX‑induced peripheral neuropathy [34,35]. Moreover, diabetes mellitus causes systemic microvascular injury and may increase ME risk through overlapping mechanisms, including hyperglycaemia-induced oxidative stress, chronic inflammation and endothelial dysfunction [36,37]. Although it remains uncertain whether diabetes mellitus increases the incidence of medication-induced ME, our findings suggest that it may contribute to PTX-associated ME. A theoretical association between prostaglandin analogue eye drops and ME has been proposed, as prostaglandins increase vascular permeability and may disrupt the blood–retinal barrier, leading to macular fluid accumulation [38]. Several case series have described ME development following initiation of these eye drops in patients already receiving other glaucoma treatments [39]. These findings imply a potentially higher ME risk compared with alternative glaucoma therapies or a synergistic interaction with concomitant medications. In contrast, few reports have described ME following prostaglandins administered via non-ophthalmic routes [40]. Additionally, ME development has been linked to factors such as retinal disease, ocular surgery, aphakia or subluxated intraocular lens rather than prostaglandin analogue eye drops alone [9,21]. Thus, the administration route of prostaglandin may be relevant when evaluating PTX-associated ME. This study has several limitations that affect interpretation. First, because JADER comprises spontaneous reports, reporting biases, including underreporting, notoriety bias, ripple effects and the Weber effect, are unavoidable [41]. Second, reports with missing data such as sex, age, body weight, and reporting year in JADER were excluded from the present analysis, resulting in the exclusion of more than one million reports, which may have introduced selection bias. Third, the database lacks information on patients receiving PTX without adverse effects, precluding incidence estimation. Fourth, dosage and detailed regimens were unavailable for analysis. Finally, reports involving prostaglandin analogue eye drops often co-existed with ocular diseases such as retinal disease and history of ocular surgery [9,21,38]. Therefore, prostaglandin analogue eye drops might be a confounding factor in the detection of signals for ME. These limitations underscore the need for prospective studies incorporating detailed clinical data, including dosage, treatment duration, ocular history and comprehensive ophthalmologic assessments, to better define the risk factors and mechanisms of PTX‑induced ME. In conclusion, our results indicate that PTX formulations are associated with an increased reporting signal of ME. Furthermore, diabetes mellitus and prostaglandin analogue eye drops may further elevate this risk. However, early ophthalmic monitoring could facilitate timely detection of PTX-associated ME. Further large-scale studies are warranted to validate these findings and clarify underlying mechanisms. Supporting information Top 10 most frequently co‑administered drugs in the macular oedema reports. (DOCX) Reports of co-existing cancers, co-administered anti-cancer drugs and macular oedema in cases involving paclitaxel use. (DOCX) Reports of co-existing cancers, co-administered anti-cancer drugs and macular oedema in cases involving nab-paclitaxel use. (DOCX) 13 May 2026 -->PONE-D-26-18562-->-->Real‑world analysis of macular oedema associated with paclitaxel formulations using the Japanese Adverse Drug Event Report database-->-->PLOS One Dear Dr. Takeda, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jun 27 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. --> If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Junzheng Yang Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please provide a complete Data Availability Statement in the submission form, ensuring you include all necessary access information or a reason for why you are unable to make your data freely accessible. If your research concerns only data provided within your submission, please write "All data are in the manuscript and/or supporting information files" as your Data Availability Statement. 3. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: This is a well-conducted and clinically relevant pharmacovigilance study addressing an uncommon but potentially vision-threatening adverse effect of paclitaxel therapy. The manuscript is interesting to read, clearly written, and tackles an important question with practical implications for oncologists, ophthalmologists, and pharmacists. The use of the Japanese Adverse Drug Event Report database provides a valuable real-world perspective, and the finding of stronger reporting signals with nab-paclitaxel, as well as the identification of diabetes mellitus and prostaglandin analogue eye drops as potential risk factors, adds useful clinical insight. The study is generally well structured, with appropriate statistical methods and a balanced discussion of the inherent limitations of spontaneous reporting databases. I particularly appreciated that the authors avoided overstating causality and appropriately framed the results as signal detection and hypothesis generation. A few points could further strengthen the manuscript. First, the rationale for excluding more than one million reports with missing covariate data should be discussed in greater detail, as this may introduce selection bias. Second, although the discussion mentions the possible influence of dose and cancer type, it would be helpful to clarify more explicitly how the lack of dosage, treatment duration, and ophthalmic baseline data may have affected the interpretation of the observed signals. Third, because prostaglandin analogue eye drops may themselves be associated with macular oedema, the possibility of confounding by underlying ocular disease deserves a little more emphasis. Overall, this is a good and informative study that contributes meaningful real-world evidence on paclitaxel-associated macular oedema. With minor clarification of the above points, the manuscript would be further strengthened. Reviewer #2: This is a concise and clinically relevant manuscript that effective connects the risk of Macular Edema (ME) with use of Paclitaxel in clinical trials. The author highlighted an important AE association; ME and PTX exposure while accounting for other variables. The reviewer thinks that the authors implied multivariable logistic regression while using the term multivariate logistic regression. ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: Yes: Dr. Melchizedek Ignatius Munaje Reviewer #2: Yes: Chidi Asuzu ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. --> 30 Jun 2026 I have attached a Word file containing my response to the reviewer and editor. Submitted filename: PLOS ONE_review_revise.ver.3.docx 15 Jul 2026 Real‑world analysis of macular oedema associated with paclitaxel formulations using the Japanese Adverse Drug Event Report database PONE-D-26-18562R1 Dear Dr. Takeda, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Junzheng Yang Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #2: All comments have been addressed ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #2: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #2: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #2: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #2: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #2: My concerns were reviewed and properly addressed. Current revision also strengthens this paper and supports the evidence on paclitaxel-associated macular edema ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #2: Yes: Chidi Asuzu ********** PONE-D-26-18562R1 PLOS One Dear Dr. Takeda, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Director Junzheng Yang Academic Editor PLOS One